Clinical Trial: Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: An Open Label, Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation

Brief Summary: To determine if Rituximab administered after allogeneic transplantation decreases the incidence of chronic GvHD

Detailed Summary: To test if prophylactic Rituximab given to 35 patients 60-90 days after allogeneic transplantation will prevent chronic Graft-versus-Host Disease
Sponsor: Stanford University

Current Primary Outcome: chronic GVHD incidence [ Time Frame: 1.5 years ]

Original Primary Outcome: Chronic GVHD

Current Secondary Outcome:

  • Relapse [ Time Frame: 5 years ]
  • nonrelapse mortality [ Time Frame: 5 years ]


Original Secondary Outcome: Relapse, non-relapse mortality

Information By: Stanford University

Dates:
Date Received: September 14, 2005
Date Started: June 2005
Date Completion:
Last Updated: March 11, 2011
Last Verified: March 2011